Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Guselkumab Subcutaneous Induction Therapy in Moderately to Severely Active Ulcerative Colitis
2022-000365-41Phase 3Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in autoimmune colitis comparing Guselkumab SC induction with Placebo SC induction (2 arms). Primary endpoint: Clinical remission. Started Oct 2022; status: active.
02
Drugs
guselkumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2022-000365-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000365-41.